Table 3.
Summary of response rates to vinorelbine-based salvage treatments
| Response | Overall | Single agent vinorelbine | Vinorelbine + other chemotherapies | Continuing trastuzumab | Stopping Trastuzumab |
| N60 | N 391 | N 21 | N 29 | N 31 | |
| ORR | 17 (28%) | 9 (23%) | 8 (38%)2 | 6 (21%) | 11 (36%)3 |
| CR | 1 (2%) | 0 (0%) | 1 (5%) | 0 (0%) | 1 (3%) |
| PR | 16 (27%) | 9 (23%) | 7 (33%) | 6 (21%) | 10 (32%) |
| SD | 16 (27%) | 12 (31%) | 4 (19%) | 8 (28%) | 8 (26%) |
| PD | 27 (45%) | 18 (46%) | 9 (43%) | 15 (52%) | 12 (39%) |
| CB (CR+PR+SD ≥ 6 months) | 30 (50%) | 15 (38%) | 11 (52%) | 13 (48%) | 18 (58%) |
ORR; overall response rate (CR+ PR); CR, complete remission: PR, partial response; SD, stable disease; PD, progressive disease; CB, clinical benefit
126 of these patients received single-agent chemotherapy with vinorelbine and continued trastuzumab beyond progression
2Two tailed Fisher's Exact test for the difference in ORR (CR+PR) = 0.24
3 Two tailed Fisher's Exact test for the difference in ORR (CR+PR) = 0.26